When used alone after 2 prior chemotherapies for metastatic breast cancer (mBC), HALAVEN is the only chemotherapy that has been proven in a clinical trial to help some women live longer.
In this trial of more than 750 women, HALAVEN was compared with other chemotherapies or hormone therapies commonly used to treat mBC. Although some women lived longer and some women did not live as long, women who were treated with HALAVEN lived an average of 13.2 months compared with women treated with other chemotherapy or hormone therapy, who lived an average of 10.6 months.
This means that women who received HALAVEN lived 25% longer than women who received other chemotherapy or hormone therapy.
HALAVEN was studied in women with all types of tumor receptors. This means that their ER/PR hormone receptors (estrogen/progesterone receptors) were either positive or negative and their HER2 receptors (human epidermal growth factor receptor 2) were either positive or negative.